Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes.

Estrogen receptor (ER)-negative breast carcinomas do not respond to hormone therapy, making their effective treatment very difficult. The re-expression of ERalpha in ER-negative MDA-MB-231 breast cancer cells has been used as a model system, in which hormone-dependent responses can be restored. Paradoxically, in contrast to the mitogenic activity of 17beta-estradiol (E2) in ER-positive breast cancer cells, E2 suppresses proliferation in ER-negative breast cancer cells in which ERalpha has been re-expressed. We have used global gene expression profiling to investigate the mechanism by which E2 suppresses proliferation in MDA-MB-231 cells that express ERalpha through adenoviral infection. We show that a number of genes known to promote cell proliferation and survival are repressed by E2 in these cells. These include genes encoding the anti-apoptosis factor SURVIVIN, positive cell cycle regulators (CDC2, CYCLIN B1, CYCLIN B2, CYCLIN G1, CHK1, BUB3, STK6, SKB1, CSE1 L) and chromosome replication proteins (MCM2, MCM3, FEN1, RRM2, TOP2A, RFC1). In parallel, E2-induced the expression of the negative cell cycle regulators KIP2 and QUIESCIN Q6, and the tumour-suppressor genes E-CADHERIN and NBL1. Strikingly, the expression of several of these genes is regulated in the opposite direction by E2 compared with their regulation in ER-positive MCF-7 cells. Together, these data suggest a mechanism for the E2-dependent suppression of proliferation in ER-negative breast cancer cells into which ERalpha has been reintroduced.

[1]  B. van der Burg,et al.  Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells. , 1989, Molecular and cellular endocrinology.

[2]  E. Lobenhofer,et al.  Regulation of DNA replication fork genes by 17beta-estradiol. , 2002, Molecular endocrinology.

[3]  Steven C. Lawlor,et al.  GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways , 2002, Nature Genetics.

[4]  R. Sutherland,et al.  Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2* , 1997, The Journal of Biological Chemistry.

[5]  J. Blow,et al.  Replication licensing — Origin licensing: defining the proliferative state? , 2002 .

[6]  C. Klinge.  Estrogen receptor interaction with estrogen response elements. , 2001, Nucleic acids research.

[7]  S. Reed,et al.  Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover , 2003, Nature Reviews Molecular Cell Biology.

[8]  A. Philips,et al.  FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. , 1998, Molecular endocrinology.

[9]  D. Coppock,et al.  The quiescin Q6 gene (QSCN6) is a fusion of two ancient gene families: thioredoxin and ERV1. , 1998, Genomics.

[10]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[11]  J. Laborda,et al.  36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. , 1991, Nucleic acids research.

[12]  B. Katzenellenbogen,et al.  Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells , 1999, Molecular and Cellular Endocrinology.

[13]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Blow,et al.  Replication licensing--defining the proliferative state? , 2002, Trends in cell biology.

[15]  H. Rochefort,et al.  Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .

[17]  Guoying Liu,et al.  NetAffx: Affymetrix probesets and annotations , 2003, Nucleic Acids Res..

[18]  E. Lobenhofer,et al.  Regulation of DNA Replication Fork Genes by 17β-Estradiol , 2002 .

[19]  John H. White,et al.  Genome-wide identification of high-affinity estrogen response elements in human and mouse. , 2004, Molecular endocrinology.

[20]  J. Bard,et al.  Ontologies in biology: design, applications and future challenges , 2004, Nature Reviews Genetics.

[21]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. , 2001, Cancer research.

[22]  M. Pike,et al.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.

[23]  S. Baylin,et al.  Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. , 1994, Cancer research.

[24]  Patricia A. Dyck,et al.  Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. , 2002, Cancer research.

[25]  Adrian V. Lee,et al.  Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. , 2003, Cancer research.

[26]  H. Rochefort,et al.  How to target estrogen receptor-negative breast cancer? , 2003, Endocrine-related cancer.

[27]  K. Korach,et al.  The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[28]  V. Giguère,et al.  Coregulators of estrogen receptor action. , 2002, Critical reviews in eukaryotic gene expression.

[29]  E. Gelmann,et al.  Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. , 1986, Cancer research.

[30]  Carlos S. Moreno,et al.  MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer , 2003, Cell.

[31]  S. Baylin,et al.  Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.

[32]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[33]  J. Herman,et al.  Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. , 2000, Cancer research.

[34]  H. Vodermaier.  Cell cycle: Waiters serving the Destruction machinery , 2001, Current Biology.

[35]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[36]  M. Hatano,et al.  Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Orphanides,et al.  Characterisation of the molecular responses to xenoestrogens using gene expression profiling , 2002, Phytochemistry Reviews.

[38]  F. Bresciani,et al.  Estrogen stimulates transcription of c-jun protooncogene. , 1990, Molecular endocrinology.

[39]  U. Thorgeirsson,et al.  Altered Localization of Retinoid X Receptor α Coincides with Loss of Retinoid Responsiveness in Human Breast Cancer MDA-MB-231 Cells , 2004, Molecular and Cellular Biology.

[40]  P. Chambon,et al.  Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[41]  V. Jordan,et al.  Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[42]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[43]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[44]  Preventing hormone-dependent breast cancer in high-risk women. , 2003, Journal of the National Cancer Institute.

[45]  T. Ozaki,et al.  Overexpression of DAN gene product in normal rat fibroblasts causes a retardation of the entry into the S phase. , 1995, Cancer research.

[46]  P. Argos,et al.  Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A , 1986, Nature.

[47]  Neil J. McKenna,et al.  Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.

[48]  M. Campiglio,et al.  Biologic and therapeutic role of HER2 in cancer , 2003, Oncogene.

[49]  G. Orphanides,et al.  Estrogen receptors: orchestrators of pleiotropic cellular responses , 2001, EMBO reports.